Analyst firms · Morgan Stanley · ABMD

Morgan Stanley ABMD price target and rating history

ABIOMED Inc. (ABMD) · Health Care

Morgan Stanley rates ABIOMED Inc. (ABMD) Equal-Weight with a $380 price target, as of its latest action on Nov 2, 2022. It has published 3 rating actions on ABMD since January 2022, including 1 upgrade and 0 downgrades.

Current rating
Equal-Weight
Price target
$380
Median target, all firms
Too few
Actions on ABMD
3

Morgan Stanley price target on ABMD

$380$328$2752023202420252026
Morgan Stanley price target on ABMD, each point a stated target, January 2022 to November 2022.

Every Morgan Stanley rating on ABMD

Questions about Morgan Stanley and ABMD

What is Morgan Stanley's price target for ABMD?
Morgan Stanley's latest stated price target for ABIOMED Inc. (ABMD) is $380, from its action on Nov 2, 2022.
What is Morgan Stanley's rating on ABMD?
Morgan Stanley rates ABMD Equal-Weight, a neutral rating, as of Nov 2, 2022.
When did Morgan Stanley last change its view on ABMD?
On Nov 2, 2022, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $235 to $380.

More ABMD rating histories

All Morgan Stanley ratingsABMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.